The pharmacotherapy of acute viral hepatitis B: a clinical pharmacist's view

Abstract

Aim. To conduct the analysis and estimation of acute viral hepatitis B pharmacotherapy through identification of drug-related problems; to form a list of recommendations with elements of pharmaceutical care concerning some aspects of acute viral hepatitis B pharmacotherapy. Materials and Methods. The objects of research: 27 medical records of patients with acute viral hepatitis B who were hospitalized to one of Lviv City Hospitals in the first quarter of 2016; medical and technological documents on acute viral hepatitis B management; results of clinical research and clinical case reports; The Pharmaceutical Care Network Europe classification (version 5.01) for drug-related problems. Methods: systemic approach, clinical-pharmaceutical, clinical-pharmacological, statistical, and analytical. Results and Discussion. All patients with acute hepatitis B received only pathogenetic and/or symptomatic pharmacotherapy which corresponds to modern scientific approaches of rational pharmacotherapy of acute hepatitis B. The total number of identified drug-related problems was 192 (a mean of 7,1±1,4 drug-related problems per patient), out of them: 30,1% - potential drug-drug interactions; 27,5% - insufficient dosage of drugs; 14,6% - co-administration of medications with the same active ingredients (duplicate prescriptions); 11,5% - excessive duration of pharmacotherapy; 6,3% - incorrect drugs; 4,7% - incorrect route of drug administration; 1,6% - contraindicated use of drugs; 1,6% - excessive dosage of drugs; 1,6% - technical drug-related problems; and 0,5% - insufficient duration of pharmacotherapy. Conclusions. According to the results of this study, the list of clinical pharmacist's recommendations (messages of pharmaceutical care) have been formed which can be used for improving the quality and safety of pharmacotherapy.

Keywords

• clinical pharmacist, acute viral hepatitis b, drug-related problems, rational pharmacotherapy